| Description | Nelonemdaz (Neu2000) is an NMDA receptor antagonist with antioxidant activity and neuroprotective activity used in the study of cerebral infarction reperfusion injury and acute ischemic stroke. |
| In vitro | Nelonemdaz （0.19-12.5 μM）以剂量依赖性方式减少抗霉素A诱导的 ROS/RNS 形成的量并抑制丙二醛（MDA）的形成[3]。 |
| In vivo | 在体重为 260-300g 的雄性斯普拉格-道利大鼠（剪夹闭塞模型）中，Nelonemdaz（0.5-20 mg/kg;再灌注后 5 分钟内静脉注射）产生了显著的神经保护作用[1]。 |
| Synonyms | Salfaprodil free base, Neu2000 |
| molecular weight | 383.22 |
| Molecular formula | C15H8F7NO3 |
| CAS | 640290-67-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 100 mg/mL (260.95 mM), Sonication is recommended. |
| References | 1. Gwag BJ, et al. Marked prevention of ischemic brain injury by Neu2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazine. J Cereb Blood Flow Metab. 2007 Jun;27(6):1142-51. 2. Sung IC, et al. Neu2000, an NR2B-selective, Moderate NMDA Receptor Antagonist and Potent Spin Trapping Molecule for Stroke. Drug News Perspect. 2010 Nov; 23(9): 549-56. 3. Nishant PV, et al. Antioxidant Properties of Neu2000 on Mitochondrial Free Radicals and Oxidative Damage. Toxicol In Vitro. 2013 Mar; 27(2): 788-97. |